Johnson & Johnson's Rybrevant (amivantamab) is showing promise in metastatic colorectal cancer, potentially offering a new treatment option for patients with RAS/BRAF wild-type tumors. Phase II data from the OrigAMI-1 study, presented at the European Society of Medical Oncology (ESMO) conference, indicate that Rybrevant in combination with chemotherapy (mFOLFOX6 or FOLFIRI) achieved an objective response rate (ORR) of 49% in first- or second-line treatment settings.
The OrigAMI-1 trial evaluated Rybrevant plus chemotherapy in patients with metastatic colorectal cancer lacking RAS or BRAF mutations. The study's findings suggest that the bispecific antibody could potentially make certain patients eligible for curative surgery, representing a significant advancement in treatment strategies. Johnson & Johnson (NYSE:JNJ) is planning to advance Rybrevant into two Phase III studies in colorectal cancer based on these encouraging Phase II results.
Clinical Implications
The observed ORR of 49% highlights the potential of Rybrevant to improve outcomes for patients with metastatic colorectal cancer. The possibility of rendering patients eligible for curative surgery underscores the clinical significance of this treatment approach. These data provide further support for targeting two oncogenic pathways with a single compound, offering a novel strategy in cancer therapy.
Future Development
Based on the Phase II data, Johnson & Johnson intends to initiate two Phase III trials to further investigate the efficacy and safety of Rybrevant in colorectal cancer. These studies will help to define the role of Rybrevant in the treatment landscape and its potential to address unmet medical needs in this patient population.
